Terms: = Endocrine gland cancer AND TRRAP, TR-AP, 8295, ENSG00000196367, Q9Y4A5, PAF400, PAF350/400, FLJ10671, STAF40, Tra1 AND Clinical Outcome
14 results:
1. Machine learning-based clinical outcome prediction in surgery for acromegaly.
Zanier O; Zoli M; Staartjes VE; Guaraldi F; Asioli S; Rustici A; Picciola VM; Pasquini E; Faustini-Fustini M; Erlic Z; Regli L; Mazzatenta D; Serra C
Endocrine; 2022 Feb; 75(2):508-515. PubMed ID: 34642894
[TBL] [Abstract] [Full Text] [Related]
2. Development and validation of an individualized nomogram for predicting the high-volume (> 5) central lymph node metastasis in papillary thyroid microcarcinoma.
Wei X; Min Y; Feng Y; He D; Zeng X; Huang Y; Fan S; Chen H; Chen J; Xiang K; Luo H; Yin G; Hu D
J Endocrinol Invest; 2022 Mar; 45(3):507-515. PubMed ID: 34491546
[TBL] [Abstract] [Full Text] [Related]
3. High EMSY expression defines a BRCA-like subgroup of high-grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum.
Hollis RL; Churchman M; Michie CO; Rye T; Knight L; McCavigan A; Perren T; Williams ARW; McCluggage WG; Kaplan RS; Jayson GC; Oza A; Harkin DP; Herrington CS; Kennedy R; Gourley C
Cancer; 2019 Aug; 125(16):2772-2781. PubMed ID: 31154673
[TBL] [Abstract] [Full Text] [Related]
4. Epitope-Specific Antitumor Immunity Suppresses Tumor Spread in Papillary Thyroid cancer.
Ehlers M; Kuebart A; Hautzel H; Enczmann J; Reis AC; Haase M; Allelein S; Dringenberg T; Schmid C; Schott M
J Clin Endocrinol Metab; 2017 Jul; 102(7):2154-2161. PubMed ID: 27860539
[TBL] [Abstract] [Full Text] [Related]
5. Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer.
Knutson KL; Maurer MJ; Preston CC; Moysich KB; Goergen K; Hawthorne KM; Cunningham JM; Odunsi K; Hartmann LC; Kalli KR; Oberg AL; Goode EL
Cancer Immunol Immunother; 2015 Dec; 64(12):1495-504. PubMed ID: 26298430
[TBL] [Abstract] [Full Text] [Related]
6. Differentially expressed miRNAs in cancer-stem-like cells: markers for tumor cell aggressiveness of pancreatic cancer.
Bao B; Ali S; Ahmad A; Li Y; Banerjee S; Kong D; Aboukameel A; Mohammad R; Van Buren E; Azmi AS; Sarkar FH
Stem Cells Dev; 2014 Aug; 23(16):1947-58. PubMed ID: 24734907
[TBL] [Abstract] [Full Text] [Related]
7. Clinico-pathological characteristics and clinical outcome of different histological types of pancreatic cancer in a large Middle European series.
Stotz M; Eisner F; Szkandera J; Absenger G; Kornprat P; Lackner C; Samonigg H; Gerger A; Pichler M
J Clin Pathol; 2013 Sep; 66(9):753-7. PubMed ID: 23750038
[TBL] [Abstract] [Full Text] [Related]
8. The genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a defined founder population associated with patient outcome.
Wojnarowicz PM; Oros KK; Quinn MC; Arcand SL; Gambaro K; Madore J; Birch AH; de Ladurantaye M; Rahimi K; Provencher DM; Mes-Masson AM; Greenwood CM; Tonin PN
PLoS One; 2012; 7(9):e45484. PubMed ID: 23029043
[TBL] [Abstract] [Full Text] [Related]
9. CD133 expression associated with poor prognosis in ovarian cancer.
Zhang J; Guo X; Chang DY; Rosen DG; Mercado-Uribe I; Liu J
Mod Pathol; 2012 Mar; 25(3):456-64. PubMed ID: 22080056
[TBL] [Abstract] [Full Text] [Related]
10. Adrenal cortical neoplasms in children: why so many carcinomas and yet so many survivors?
Dehner LP; Hill DA
Pediatr Dev Pathol; 2009; 12(4):284-91. PubMed ID: 19326954
[TBL] [Abstract] [Full Text] [Related]
11. Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study.
Schilder RJ; Sill MW; Lee RB; Shaw TJ; Senterman MK; Klein-Szanto AJ; Miner Z; Vanderhyden BC
J Clin Oncol; 2008 Jul; 26(20):3418-25. PubMed ID: 18612157
[TBL] [Abstract] [Full Text] [Related]
12. A combination of platinum and tamoxifen in advanced ovarian cancer failing platinum-based chemotherapy: results of a Phase II study.
Benedetti Panici P; Greggi S; Amoroso M; Scambia G; Battaglia FA; Gebbia V; Salerno G; Paratore MP; Mancuso S
Int J Gynecol Cancer; 2001; 11(6):438-44. PubMed ID: 11906546
[TBL] [Abstract] [Full Text] [Related]
13. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
Konecny G; Untch M; Arboleda J; Wilson C; Kahlert S; Boettcher B; Felber M; Beryt M; Lude S; Hepp H; Slamon D; Pegram M
Clin Cancer Res; 2001 Aug; 7(8):2448-57. PubMed ID: 11489825
[TBL] [Abstract] [Full Text] [Related]
14. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
[TBL] [Abstract] [Full Text] [Related]
